Gastroduodenitis

Summary

Gastroduodenitis (MONDO:0004628) is a disease with 2 GWAS associations across 13 studies and 1 clinical trial. A subtype of gastric ulcer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 2
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastroduodenitis
Mondo ID	MONDO:0004628
DOID	DOID:8644
SNOMED CT	196731005
UMLS	C0267166
MedGen	540445
Is cancer (heuristic)	no

Data availability: 2 GWAS associations (13 studies).

Disease family

This is a subtype of gastric ulcer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › peptic ulcer disease › gastric ulcer › gastroduodenitis

Genetics & variants

GWAS landscape

2 GWAS associations across 13 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs1520715	2e-07	LINC00882	?
rs9884152	5e-07	ATP8A1-DT - RN7SKP82	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90436317	Zhou W	2018	28,941	378,124	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90478347	Verma A	2024	20,797	394,987	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651932	Liu TY	2025	11,580	197,546	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478358	Verma A	2024	8,968	419,908	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478346	Verma A	2024	7,308	103,005	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480857	Verma A	2024	7,308	103,005	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478357	Verma A	2024	3,133	111,302	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480833	Verma A	2024	3,133	111,302	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478345	Verma A	2024	3,071	51,836	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90652156	Liu TY	2025	2,938	197,546	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	2

MAF distribution

Bucket	Variants
common (>=0.05)	2
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	1
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs1520715	3	106756962	A>G	0.05	intron_variant	LINC00882	2e-07	Tier 4: intronic/intergenic
rs9884152	4	42864278	G>A,C	0.05	intergenic_variant	ATP8A1-DT - RN7SKP82	5e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04702542	Not specified	ACTIVE_NOT_RECRUITING	To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children.